Navidea biopharmaceuticals announces $5 million private placement with existing investor

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that it has executed an agreement with the company's largest shareholder, john k. scott, jr., to purchase $5 million of newly-designated series e redeemable convertible preferred stock. over the next 18 months, the series e preferred can be converted into approx
NAVB Ratings Summary
NAVB Quant Ranking